Methyl-CpG-binding protein 2 mediates antifibrotic effects in scleroderma fibroblasts

Area of Science:

• Epigenetics
• Dermatology
• Molecular Biology

Background:

• Scleroderma (SSc) pathogenesis involves epigenetic dysregulation.
• Methyl-CpG-binding protein 2 (MeCP2) is a crucial epigenetic regulator.
• The role of MeCP2 in SSc fibroblast activation and fibrosis is not well understood.

Purpose of the Study:

• To investigate the role of MeCP2 in fibroblast activation and fibrosis in SSc.
• To identify MeCP2-regulated genes involved in SSc pathogenesis.
• To explore potential therapeutic targets for SSc based on MeCP2 function.

Main Methods:

• Fibroblast isolation from SSc patients and healthy controls.
• Assessment of MeCP2 expression via qPCR and Western blot.
• In vitro assays for myofibroblast differentiation, proliferation, and migration.
• RNA-sequencing and ChIP-sequencing to identify MeCP2 targets and binding sites.

Main Results:

• MeCP2 expression is elevated in SSc fibroblasts.
• MeCP2 overexpression suppresses myofibroblast differentiation, proliferation, and migration.
• MeCP2 regulates fibrosis-associated genes including PLAU, NID2, and ADA.
• MeCP2 directly binds to regulatory regions of NID2 and PLAU.

Conclusions:

• MeCP2 exhibits antifibrotic effects in SSc.
• MeCP2 modulates fibroblast behavior and extracellular matrix components.
• MeCP2-regulated genes like PLAU, NID2, and ADA are potential therapeutic targets for SSc.